Boheng Zhang

机构：Fudan University, Zhongshan Hospital of Xiamen University, Zhongshan Hospital, Ministry of Education, Tangshan Gongren Hospital · ORCID：0000-0002-9603-7179

发表论文 117 篇 · 总被引 6405 次 · h-index 35

代表论文

• The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment (2025 · The Lancet · 被引 167)
• Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study (2022 · Liver Cancer · 被引 50)
• Development of the Scientific, Transparent and Applicable Rankings (STAR) tool for clinical practice guidelines (2023 · Chinese Medical Journal · 被引 27)
• Efficacy of Transarterial Chemoembolization Combined with Molecular Targeted Agents for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis (2022 · Cancers · 被引 18)
• CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway (2024 · Hepatology International · 被引 16)
• Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma (2024 · Journal of Cancer Research and Clinical Oncology · 被引 15)